The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors.
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Honoraria - Clinical Care Options
Consulting or Advisory Role - Abbvie (Inst); BostonGene (Inst); BostonGene (Inst); BridgeBio Pharma (Inst); EMD Serono; Fujifilm (Inst); Inspirna (Inst); Jubilant Pharmaceuticals (Inst); Merck (Inst); Navire (Inst); Predicine (Inst); Regeneron (Inst); Sanofi (Inst); Silicon Therapeutics (Inst); Silicon Therapeutics (Inst); Teon Therapeutics (Inst); Turning Point Therapeutics (Inst)
Speakers' Bureau - Total Health Conferencing
Research Funding - 3-V Biosciences (Inst); Abbisko (Inst); Abbvie (Inst); ABL Bio (Inst); Accutar Biotech (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); American Society of Clinical Oncology (Inst); Amgen (Inst); ARMO BioSciences (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioatla (Inst); BioInvent (Inst); Biomea Fusion (Inst); Biothera (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Celldex (Inst); Centessa Pharmaceuticals (Inst); Ciclomed (Inst); Conjupro Biotherapeutics (Inst); Curegenix (Inst); Curis (Inst); Cyteir (Inst); Daiichi (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); Eikon Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Freenome (Inst); Fujifilm (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Harbour BioMed (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IgM Biosciences (Inst); Ignyta (Inst); Immunitas (Inst); Immunogen/MacroGenics (Inst); Incyte (Inst); Jacobio (Inst); Jazz Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Jubilant Pharmaceuticals (Inst); Kineta (Inst); Kolltan Pharmaceuticals (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); MD Anderson Cancer Center (Inst); MedImmune (Inst); Merck (Inst); Metabomed (Inst); Millennium (Inst); Mirati Therapeutics (Inst); miRNA Therapeutics (Inst); Molecular Templates (Inst); National Institute of Health (NIH) (Inst); Navire (Inst); NGM Biopharmaceuticals (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Nuvectis Pharma (Inst); OncoMed (Inst); Oncorus (Inst); Oncothyreon (Inst); Phanes Therapeutics (Inst); Poseida (Inst); Precision Oncology (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyramid Biosciences (Inst); Pyxis (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Roche (Inst); Samumed (Inst); Sapience Therapeutics (Inst); Sarah Cannon Research Institute (Inst); Seagen (Inst); Silicon Therapeutics (Inst); Simcha Therapeutics (Inst); Sirnaomics (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tallac Therapeutics (Inst); Tango Therapeutics (Inst); Tarus Therapeutics (Inst); Tarveda Therapeutics (Inst); TeneoBio (Inst); Tesaro (Inst); Tocagen (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst); Xencor (Inst); Zhuhai Yufan Biotechnologies (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute; Synthorx/Sanofi
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; ABL Bio; Actuate Therapeutics; Agenus; Amgen; AstraZeneca; Atreca; BAKX Therapeutics; Boehringer Ingelheim; Compass Therapeutics; Cullinan Oncology; DAAN Biotherapeutics; EMD Serono; GlaxoSmithKline; I-Mab; ImCheck therapeutics; IQvia; Kineta; Kyowa Kirin International; Mekanistic Therapeutics; Mersana; Molecular Templates; Neurotrials Research; Pfizer; QED Therapeutics; Qualigen Therapeutics; Quanta Therapeutics; Relay Therapeutics; Roche/Genentech; Roivant; Scenic Biotech; Schrodinger; Seagen; Sotio; ST Cube; Stemline Therapeutics; Takeda; Zentalis
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Jonathan W. Goldman
Consulting or Advisory Role - AbbVie; AstraZeneca; Bristol-Myers Squibb; Genentech; Gritstone Bio; Janssen; Jazz Pharmaceuticals; Lilly; Pfizer; Puma Biotechnology; Regeneron; Turning Point Therapeutics
Research Funding - Abbvie (Inst); Advaxis (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
 
Anthony B. El-Khoueiry
Honoraria - ABL bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; EISAI; Exelixis; Merck; QED Therapeutics; Qurient; Roche/Genentech; Senti Biosciences; SERVIER; Tallac Therapeutics
Consulting or Advisory Role - ABL Bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; QED Therapeutics; Qurient; Roche; Senti Biosciences; SERVIER; Tallac Therapeutics
Research Funding - Astex Pharmaceuticals; AstraZeneca; Auransa; Fulgent Genetics
Travel, Accommodations, Expenses - Affimed Therapeutics
 
Anthony W. Tolcher
Employment - Next Oncology
Leadership - Next Oncology
Stock and Other Ownership Interests - Immunome; Pyxis (Inst)
Consulting or Advisory Role - AbbVie (Inst); Aclaris Therapeutics (Inst); Adagene (Inst); Affinia Therapeutics (Inst); Agenus (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Aximmune (Inst); Bayer (Inst); BioInvent (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bright Peak Therapeutics (Inst); Cullinan Oncology (Inst); Daiichi Sankyo, Inc. (Inst); Deka Biosciences (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Exelixis (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); HiberCell (Inst); IDEA Pharma (Inst); Ikena Oncology (Inst); Immuneering (Inst); Immunome (Inst); Immunomet (Inst); IMPAC Medical Systems (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Karma Oncology (Inst); Kirilys Therapeutics (Inst); Lengo Therapeutics (Inst); Lilly (Inst); Link Immunotherapeutics (Inst); Medicxi (Inst); Mekanistic Therapeutics (Inst); Menarini (Inst); Mersana (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Nerviano Medical Sciences (Inst); Nested Therapeutics (Inst); Novo Nordisk (Inst); Nurix (Inst); Ocellaris Pharma (Inst); Partner Therapeutics (Inst); Pfizer (Inst); Pheon Therapeutics (Inst); Pierre Fabre (Inst); Pyramid Biosciences (Inst); Pyxis (Inst); Qualigen Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Senti Biosciences (Inst); Singzyme Pte Ltd (Inst); SK Life Sciences (Inst); Sotio (Inst); Spirea (Inst); Sun Pharma Advanced Research Company (Inst); TheraTechnologies (Inst); Transcenta (Inst); Transgene (Inst); Trillium Therapeutics (Inst); Venus Oncology (Inst); Verastem (Inst); Vincerx Pharma (Inst); VRise Therapeutics (Inst); Zentalis (Inst); ZielBio (Inst)
Research Funding - AbbVie (Inst); ABL Bio (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena (Inst); Apros Therapeutics (Inst); Arcellx (Inst); ARMO BioSciences (Inst); Arrys Therapeutics (Inst); Artios (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Bioinvent (Inst); Birdie (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); CStone Pharmaceuticals (Inst); Daiichi Sankyo, Inc. (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ImmuneOncia (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Naturewise (Inst); NBE Therapeutics (Inst); NextCure (Inst); Nitto BioPharma (Inst); Odonate Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Qilu Puget Sound Biotherapeutics (Inst); Samumed (Inst); Seagen (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
Expert Testimony - Immunogen
Travel, Accommodations, Expenses - Sotio (Inst)
 
Yan Xing
No Relationships to Disclose
 
Jason Timothy Henry
Employment - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Research Funding - Abbisko (Inst); ABL Bio (Inst); accutar biotech (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); Amgen (Inst); Artios (Inst); AstraZeneca/Merck (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); Bioinvent (Inst); Biosplice (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); cyteir (Inst); DaiichI Sankyo (Inst); Daiichi Sankyo/Lilly (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fujifilm (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); Iconic Therapeutics (Inst); Iconic Therapeutics (Inst); Iconic Therapeutics (Inst); IgM Biosciences (Inst); Immunitas (Inst); Immunogen (Inst); Immunogen (Inst); Jacobio (Inst); Jazz Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Jubilant Pharmaceuticals (Inst); Jubilant Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Metabomed (Inst); Mirati Therapeutics (Inst); Molecular Templates (Inst); Navire (Inst); NiKang Therapeutics (Inst); Oncorus (Inst); Poseida therapeutics (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyramid Biosciences (Inst); Pyxis (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Sapience Therapeutics (Inst); Sarah Cannon Research Institute (Inst); Sarah Cannon Research Institute (Inst); Seagan (Inst); Simcha Therapeutics (Inst); Sirnaomics (Inst); Stingthera (Inst); StingThera (Inst); Synthorx (Inst); Synthorx (Inst); Takeda (Inst); Takeda (Inst); Tallac Therapeutics (Inst); Tarveda Therapeutics (Inst); Teneothree (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - HCA/Sarah Cannon (Inst)
 
Bhumsuk Keam
Honoraria - AstraZeneca; Bayer; LG Chem; Lilly; MSD Oncology; Yuhan
Consulting or Advisory Role - Handok; ImmuneOncia; NeoImmuneTech; TiumBio; Trial Informatics
Research Funding - AstraZeneca; MSD Oncology; Ono Pharmaceutical
 
Dong-Wan Kim
Research Funding - Alpha Biopharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); BridgeBio Pharma (Inst); Chong Kun Dang Pharmaceutical (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); IMBdx (Inst); IMBdx (Inst); inno.N (Inst); Janssen (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst); TP Therapeutics (Inst); Xcovery (Inst); Yuhan (Inst)
 
Tae-Yong Kim
No Relationships to Disclose
 
Hye Ryun Kim
Speakers' Bureau - ABL Bio; Ono Pharmaceutical; Roche/Genentech
 
Min Hee Hong
Stock and Other Ownership Interests - GI biome; GI cell
Honoraria - AstraZeneca; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Merck; Roche; Yuhan
Research Funding - Yuhan
 
Min Hwan Kim
Stock and Other Ownership Interests - AIMA company
Honoraria - AstraZeneca; Boryung Pharmaceuticals; Boryung Pharmaceuticals; Celltrion; Celltrion; Daiichi Sankyo; Eisai; MSD
Consulting or Advisory Role - Boryung Pharmaceuticals; Daiichi Sankyo; Eisai
Research Funding - AstraZeneca; Boryung Pharmaceuticals; Celltrion; Daewoong Pharmaceutical
 
Dae Ho Lee
Honoraria - Abbvie; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; ChongKeunDang Healthcare; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; ST Cube; Takeda; Yuhan
Consulting or Advisory Role - ABION; ST Cube
 
SangMi Lee
Employment - ABL Bio
Stock and Other Ownership Interests - ABL Bio Inc.
 
JuYeun Jeon
Employment - ABL Bio
 
John W. Hayslip
Employment - Abbvie; I-Mab; Nektar
Leadership - I-Mab
Stock and Other Ownership Interests - Abbvie; I-Mab
 
Cong Xu
Employment - I-Mab
Stock and Other Ownership Interests - I-Mab
 
Edward B. Garon
Consulting or Advisory Role - ABBVIE/ABBOTT; Arcus Biosciences; AstraZeneca; Atreca; BridgeBio Pharma; Bristol-Myers Squibb; EMD Serono; Gilead Sciences; Hookipa Biotech; LianBio; Lilly; Merus; Novartis; Nuvalent, Inc.; Regeneron; Sanofi; Seagan; Sensei Biotherapeutics; Sumitomo Pharma Oncology; Summit Therapeutics; Synthekine; Zymeworks
Research Funding - ABL Bio (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Synthekine (Inst)
Patents, Royalties, Other Intellectual Property - Diagnosistic and therapeutic use of "Motif Neoepitopes" as defined by Cummings et al in Nature Cancer. (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics; Novartis
Other Relationship - Daiichi Sankyo/Astra Zeneca